Timeline of incretin therapeutics: difference between revisions
Diff·revision 5 → 6·23:12, 17 Sep 2024
Difference between revision 5 and revision 6 of Timeline of incretin therapeutics. 2 lines changed; the page grew by 166 bytes.
| Revision 5 — 04:33, 30 Aug 2024 Chromatokid (talk) correct the dose ladder — the maintenance dose is not the maximum dose 2,186 bytes +341 | Revision 6 — 23:12, 17 Sep 2024 TriumphThad (talk) rm a duplicated category 2,352 bytes +166 | ||
|---|---|---|---|
| 23 | The 1986 finding is the hinge of the field: it established that the incretin axis is defective in type 2 diabetes and therefore a therapeutic target rather than only a physiological curiosity.{{r|holst2007}} | 23 | The 1986 finding is the hinge of the field: it established that the incretin axis is defective in type 2 diabetes and therefore a therapeutic target rather than only a physiological curiosity.{{r|holst2007}} |
| 24 | 24 | ||
| + | 25 | Identification of DPP-4 as the inactivating enzyme defined the engineering problem every subsequent agonist solves. See [[GLP-1 receptor agonist]].{{r|drucker2018}} | |
| + | 26 | ||
| 25 | == References == | 27 | == References == |
| 26 | {{reflist}} | 28 | {{reflist}} |